- Trial phase
- Phase 3 (ZIRCON) completed; BLA under FDA review
- Time to market
- BLA for ccRCC under FDA review per Telix's May 2026 release; US commercialization would follow an FDA decision whose date is not confirmed in available data (potentially within ~12 months of approval).
- Why 4/10
- No hard, dated binary in the next ~12 months in available data: Zircaix's ccRCC BLA was described as "pending" as of the May 2026 ZIRCON release, and no PDUFA date or approval is recorded in SecBot's FDA/catalyst data, the nearest company-level event is the September 22, 2026 R&D Day, which is not a regulatory decision, so this mid-/late-stage asset at a diversified commercial-stage company scores 4.
Watch for (1) an FDA action/PDUFA announcement on the Zircaix BLA in ccRCC, the single biggest binary for this drug, undated in available data, and (2) the September 22, 2026 R&D Day, where Telix may update Zircaix launch/regulatory timing.
Price Chart
Executive Summary
Zircaix (TLX250-Px / TLX250-CDx, zirconium-89 girentuximab) is Telix Pharmaceuticals' Phase 3-completed PET imaging agent for clear cell renal cell carcinoma, with a US BLA that Telix described as pending as of its May 2026 ZIRCON data publication. SecBot internal data (company press releases, SEC filings, FDA/catalyst tables) is the sole grounding, with real GlobeNewswire and EDGAR URLs cited.
How It Works
A PET imaging "tracer" for kidney cancer: a radioactive form of zirconium (Zr-89) is attached to an antibody (girentuximab) that binds to CAIX, a protein heavily present on clear cell renal cell carcinoma cells. Injected into a patient, it lights up suspicious kidney masses on a PET/CT scan so doctors can better tell malignant from benign lesions, the diagnostic "see" companion to Telix's therapy pipeline, which uses the same targeting antibody.
Trial Status
The pivotal Phase 3 ZIRCON trial is complete. In May 2026 Telix published an independent analysis of ZIRCON data in European Urology showing Zircaix PET/CT is highly predictive of renal malignancy across subtypes (98% positive predictive value cited); Telix noted that analysis is exploratory and separate from the pending BLA for ccRCC. No approval, CRL, or PDUFA date for Zircaix appears in SecBot's FDA/catalyst records through mid-August 2026.
The Two-Sided Case
Upcoming Catalysts
- FDA action/PDUFA announcement on the Zircaix (TLX250-CDx) BLA in clear cell renal cell carcinoma, undated in available data
- Telix R&D Day in New York City on September 22, 2026, possible Zircaix regulatory/launch timing updates
- H2 2026 quarterly updates (next earnings) for any BLA status or commercial-launch commentary
- Potential European or ex-US regulatory filings/decisions for TLX250-CDx (not confirmed in local data)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Telix Pharmaceuticals Limited PRESS-RELEASE TLX ·Originating report